On December 13, the National Medical Insurance Administration announced that the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug catalogs in 2023 has been successfully completed. The new version of the catalog will be implemented on January 1, 2024.

In this adjustment, a total of 126 drugs were newly added to the national medical insurance drug catalog, and 1 drug was removed from the catalog. 143 drugs outside the catalog participated in negotiations or bidding, of which 121 drugs were successfully negotiated or bid. The negotiation success rate was 84.6%, and the average price reduction was 61.7%. The success rate and price reduction were basically the same as in 2022.

After this round of adjustments, the total number of drugs in the national medical insurance drug catalog has reached 3,088, including 1,698 Western medicines and 1,390 Chinese patent medicines; there are still 892 types of traditional Chinese medicines.

In this adjustment, the National Medical Insurance Administration has further improved the rules and standardized procedures on the basis of strengthening research and demonstration and extensive solicitation of opinions, and the scientific nature, standardization, transparency and refinement of the catalog adjustment have been further improved. Firmly grasp the functional positioning of "guaranteeing the basics", regard the affordability of the fund as the "bottom line" that must be adhered to, do our best and within our capabilities, and strive to meet the basic drug needs of the majority of insured persons; improve the renewal rules and initially establish basic coverage Form a payment standard mechanism for the entire life cycle of new drugs to increase support for pharmaceutical innovation. At the same time, on the basis of ensuring the safety of the fund, this adjustment will continue to appropriately relax the payment scope of some categories of products in the catalog, further improving drug accessibility and fairness in drug use.

Since the establishment of the National Medical Insurance Administration, the drug catalog has been adjusted for six consecutive years, and a total of 744 drugs have been added to the national medical insurance drug catalog. At the same time, a number of drugs with uncertain efficacy, easy clinical abuse, or elimination have been removed from the catalog. Leading profound changes in the use of drugs.

Relevant statistical results from the Chinese Pharmaceutical Association show that since 2018, the proportion of medical insurance drugs used in medical institutions has increased year by year, its dominant position has been further consolidated, and the rationality of clinical drug use has been actively improved. At the same time, the entry of innovative drugs into medical insurance has been significantly accelerated, the price level of commonly used drugs has dropped significantly, and the level of drug protection for major diseases and special groups has been greatly improved, significantly reducing the drug burden of the public.
网址：
https://news.yaozh.com/archive/41141.html